New combo therapy aims to tame deadly transplant complication
NCT ID NCT07184853
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests whether adding etanercept to the standard drug ruxolitinib works better for severe graft-versus-host disease (GVHD) that doesn't respond to steroids. GVHD is a life-threatening complication after a stem cell transplant where donor cells attack the patient's body. About 122 people aged 12-70 will be randomly assigned to get either ruxolitinib alone or ruxolitinib plus etanercept, and researchers will check response at day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.